Mon, 23/10/2023 - 13:21
The GCIG INTERLACE trial has found that a short course of carboplatin and paclitaxel chemotherapy, before the usual treatment of chemoradiation, can reduce the risk of cervical cancer recurrence or mortality.
"We are delighted that the INTERLACE trial has found a new way of using existing treatments to improve cervical cancer survival and reduce the risk of recurrence. In recent decades we have seen little improvement in the survival rates of cervical cancer, and we often hear from women who feel that they face limited treatment options, or who have experienced the difficulty of their cancer returning. This new research is very welcome, and we hope to see this treatment method used in practice as soon as possible."
Eluned Hughes, Head of Information & Engagement at Jo's Cervical Cancer Trust